U.S. regulators are taking a fresh look at infant respiratory syncytial virus (RSV) antibody treatments after concerns raised by vaccine skeptics prompted Robert F. Kennedy Jr.'s health leadership team to initiate new safety inquiries.

The review marks the latest instance in which routine immunization policies are being re-examined under the current administration.

On Friday, the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted 8 to 3 to rescind the universal recommendation for a hepatitis B birth-dose vaccine for infants born to hepatitis B surface antigen–negative mothers.

Instead, recommended individual-based decision-making for parents deciding whether to give the hepatitis B vaccine, including the birth dose, to infants born to women who test negative for the virus.

Also Read: Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

For those infants not receiving the birth dose, ACIP suggested in its recommendation that the initial dose be administered no earlier than two months of age.

Reuters ...